Liver Cancer Prevention Research Unit

Studies on Molecular Cellular Pathology and Control of Liver Diseases

 

PI_photo  

Unit Leader
Soichi KOJIMA  Ph.D.

408 Main Research Building, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
Tel: +81-48-467-7938

skojima[at]riken.jp

Research Experience

“Clarification of Pathogenesis and Drug Discovery toward Hepatic Diseases” :
Identification of novel targets for drug discovery in liver diseases and high throughput screening of their regulatory compounds for future drug discovery utilizing chemical biology techniques.


  1. Screening of Novel Drugs: Drug discovery and development of new drugs (non- nucleotide analogues) against hepatitis B virus (HBV) utilizing the next generation life science technologies under financial support from AMED.
  2. Development of New Diagnosis Method: Development of diagnosis, prevention, and therapy against early stage of liver fibrosis targeting novel liver fibrogenesis marker, TGF-β LAP-DP under collaboration with medical universities and companies.
  3. Molecular Mechanism of Novel Drugs: Studies on nuclear TG2/crosslinking and inactivation of Sp1/selective apoptosis of MYCN positive liver cancer stem cells by a phase III drug candidate, acyclic retinoid (Peretinoin) and their control by foods.

News

2018/04/24 Vitamin A derivative selectively kills liver cancer stem cells
2016/03/11 How Acyclic retinoid prevents the recurrence of Liver cancer

Related Links

AMED Research Program on Hepatitis
Technique to kill selectively hepatocellular carcinoma cells by synthesized chemicals
Technique to detect tissue fibrogenesis using the antibodies against TGF-β LAP degradation products
Analysis of protein-crosslinking activity in the nucleus